Altasciences Initiates Phase I Study in Healthy Normal Subjects for ST-2427, a Non-Opioid Analgesic for Acute Pain
(0) Altasciences is pleased to support SiteOne Therapeutics with a Phase I, randomized, double-blind, placebo-controlled study in healthy adults to evaluate the safety, tolerability, and pharmacokinetics of ST-2427. ST-2427 is a highly selective inhibitor of NaV1.7 for the management of moderate-to-severe pain; by selectively targeting NaV1.7, ST-2427 aims to stop the electrical signals responsible for pain before they reach the central nervous system. Amy Denvir, General Manager of Altasciences' Kansas City clinical site, says, " We are proud to partner with SiteOne Therapeutics and help...